1. Home
  2. AMST vs IMNN Comparison

AMST vs IMNN Comparison

Compare AMST & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amesite Inc.

AMST

Amesite Inc.

HOLD

Current Price

$2.11

Market Cap

11.8M

Sector

Technology

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.57

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMST
IMNN
Founded
2017
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
12.5M
IPO Year
2020
1985

Fundamental Metrics

Financial Performance
Metric
AMST
IMNN
Price
$2.11
$3.57
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
508.1K
79.8K
Earning Date
02-09-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$193,505.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
68.56
N/A
52 Week Low
$1.79
$2.99
52 Week High
$4.78
$41.22

Technical Indicators

Market Signals
Indicator
AMST
IMNN
Relative Strength Index (RSI) 44.43 42.77
Support Level $1.87 $3.38
Resistance Level $2.15 $3.88
Average True Range (ATR) 0.13 0.33
MACD 0.03 -0.01
Stochastic Oscillator 72.22 43.81

Price Performance

Historical Comparison
AMST
IMNN

About AMST Amesite Inc.

Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: